Fundz

Watching Cumberland Pharmaceuticals Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Other EventsItem 8.01 · 8-KHIGH RiskMixed

Cumberland Pharmaceuticals Inc.

Filed: Jul 13, 2026CIK: 0001087294Health Care
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Cumberland Pharmaceuticals completed a strategic acquisition with Apotex Health Corp on July 13, 2026, receiving $100 million in cash and declaring a special dividend of $1.50 per share, signaling a major business restructuring and shareholder value return.

Key Takeaways

Cumberland sold its U.S.-branded businesses to Apotex Health Corp and received $100 million in cash at closing

Company declared a special cash dividend of $1.50 per share payable around July 31, 2026 to shareholders of record as of July 23, 2026

2 more takeaways

Related Filings (3)

3 more filings from Cumberland Pharmaceuticals Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateJul 13, 2026
Item8.01
CategoryOther Events
CIK0001087294
Accession #cpix-20260713
Risk LevelHIGH
SentimentMixed
Signalopportunity
Topics
acquisitiondivestituredividend

What This Means

Other material events not covered by specific item numbers. The content of the filing determines significance.
View Full Filing on SEC.govBrowse More Filings

Cumberland Pharmaceuticals Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.